NeoHexa stent at five years: Sirolimus power meets real-world endurance
World Journal of Cardiology · 26.07.2026 · 18 (7)
DOI: 10.4330/wjc.117872 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Cardiology, online erschienen am 26.07.2026. Verfasst von Ji-Xin Zhong und 1 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
The drug-eluting stent, which combines a mechanical scaffold with the localized release of an antiproliferative drug to prevent in-stent restenosis caused by excessive tissue growth, represents a pivotal advancement in percutaneous coronary intervention. In this continually advancing field, establishing long-term efficacy and safety data is paramount. While excellent short-term results are now expected, the true clinical value of a drug-eluting stent is determined by its durability, its ability to maintain vessel patency and prevent adverse cardiac events for many years after implantation, especially in the complex, high-risk patients encountered in real-world practice. The retrospective study by Trehan et al , published in World Journal of Cardiology , provides a much-needed, long-term lens through which to view the performance of the NeoHexa sirolimus-eluting stent in an all-comer real-world Indian population. Here, we will discuss the recent progress in studying the long-term efficacy and safety of sirolimus-eluting stent.
Zitieren
APA
Zhong, J., & Rao, X. (2026). NeoHexa stent at five years: Sirolimus power meets real-world endurance. World Journal of Cardiology, 18(7). https://doi.org/10.4330/wjc.117872
Vancouver
Zhong J, Rao X. NeoHexa stent at five years: Sirolimus power meets real-world endurance. World Journal of Cardiology. 2026;18(7). doi:10.4330/wjc.117872
BibTeX
@article{Zhong2026,
author = {Zhong, Ji-Xin and Rao, Xiao-Quan},
title = {NeoHexa stent at five years: Sirolimus power meets real-world endurance},
journal = {World Journal of Cardiology},
year = {2026},
volume = {18},
number = {7},
doi = {10.4330/wjc.117872}
}
EUVIMED